IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

Argyle have drawn three and lost six of their last nine fixtures and sit bottom of the Championship table, four points from ...

BRISTOL, Va. (WDBJ) - Fire crews were called back to the former Virginia Intermont College campus in Bristol this past ...

We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Holly Lavinder with Bristol Sportsplex, gets us ready for two clinics being conducted by French Open Doubles Champion and ESPN Analyst Luke Jensen on January 5th! Please check out the video to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A report was issued from the National Weather Service on Monday at 8:43 a.m. for heavy rain and flooding until 9:45 a.m. for ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...